​

Arcutis Biotherapeutics Ownership | Who Owns Arcutis Biotherapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Arcutis Biotherapeutics Ownership Summary

Arcutis Biotherapeutics is owned by 96.57% institutional investors, 1.93% insiders, and 1.51% retail investors. Jennison associates is the largest institutional shareholder, holding 9.93% of ARQT shares. Polar Capital Biotech S Inc is the top mutual fund, with 5.06% of its assets in Arcutis Biotherapeutics shares.

ARQT Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockArcutis Biotherapeutics96.57%1.93%1.51%
SectorHealthcare Stocks 57.39%9.93%32.68%
IndustryBiotech Stocks 68.48%9.65%21.87%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Jennison associates12.34M9.93%$171.89M
Suvretta capital management11.40M9.17%$158.79M
Rubric capital management lp10.97M8.82%$152.77M
Blackrock8.62M7.76%$80.19M
Blackrock funding, inc. /de9.15M7.36%$127.44M
Frazier life sciences management8.79M7.11%$81.70M
Polar capital7.38M5.93%$102.77M
Vanguard group6.44M5.18%$89.72M
State street4.95M3.98%$68.96M
Morgan stanley3.97M3.22%$36.95M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Pivotal bioventure partners investment advisor2.12M19.95%$29.54M
Tejara capital886.84K8.09%$12.35M
Suvretta capital management11.40M5.41%$158.79M
Frazier life sciences management8.79M3.82%$81.70M
Lion point capital, lp46.30K3.38%$644.96K
Rubric capital management lp10.97M1.96%$152.77M
Stempoint capital lp500.97K1.74%$6.98M
Cormorant asset management, lp1.82M1.40%$25.42M
Privium fund management b.v.325.71K1.03%$4.54M
Myda advisors200.00K0.70%$2.79M

Top Buyers

HolderShares% AssetsChange
Ubs group2.79M0.01%2.57M
Blackrock8.62M0.00%1.96M
Point72 asset management1.75M0.05%1.51M
Cercano management1.26M0.44%1.26M
Millennium management2.31M0.02%1.16M

Top Sellers

HolderShares% AssetsChange
Perceptive advisors---1.36M
Braidwell lp---1.30M
Stempoint capital lp500.97K1.74%-1.28M
Bain capital life sciences investors---1.03M
Franklin resources3.31M0.01%-941.10K

New Positions

HolderShares% AssetsChangeValue
Cercano management1.26M0.44%1.26M$17.49M
Driehaus capital management1.10M0.13%1.10M$15.28M
Simplify asset management742.30K0.51%742.30K$10.34M
Norges bank532.79K0.00%532.79K$7.42M
Privium fund management b.v.325.71K1.03%325.71K$4.54M

Sold Out

HolderChange
Nelson, van denburg & campbell wealth management group-22.00
Byrne asset management-100.00
Colonial trust advisors-100.00
Bessemer group-110.00
True wealth design-111.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 20242149.74%120,033,596-6.58%960.90%1073.88%6629.41%
Sep 30, 20241941.57%128,485,4751.57%1030.98%104-3.70%51-7.27%
Jun 30, 202419113.02%126,499,0251.37%1020.81%108-0.92%5544.74%
Mar 31, 202416924.26%124,792,42623.24%1120.94%10921.11%3846.15%
Dec 31, 2023136-4.23%101,262,58151.01%1090.93%9025.00%26-27.78%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Polar Capital Biotech S Inc6.00M5.06%-
Vanguard US Total Market Shares ETF3.59M3.03%492.10K
Vanguard Total Stock Mkt Idx Inv3.34M2.82%37.27K
PGIM Jennison Small Company A3.09M2.60%-
Jennison SMid Cap Core Equity3.09M2.60%-
iShares Russell 2000 ETF2.82M2.38%-24.48K
Jennison Health Sciences Equity2.27M1.91%-465.50K
PGIM Jennison Health Sciences Z2.27M1.91%-255.31K
SPDR® S&P Biotech ETF1.96M1.66%-21.06K
Franklin Biotechnology Discv A(acc)USD1.71M1.44%-112.50K

Recent Insider Transactions

DateNameRoleActivityValue
Apr 01, 2025Welgus Howard G.-Sell$151.24K
Apr 02, 2025Topper David Joseph Chief Financial OfficerSell$151.70K
Mar 24, 2025Watanabe Todd Franklin See RemarksSell$26.28K
Mar 25, 2025Watanabe Todd Franklin See RemarksSell$38.13K
Mar 17, 2025Watanabe Todd Franklin See RemarksSell$21.14K

Insider Transactions Trends

DateBuySell
2025 Q2-2
2025 Q1-18
2024 Q4314
2024 Q3-9
2024 Q2-10

ARQT Ownership FAQ

Who Owns Arcutis Biotherapeutics?

Arcutis Biotherapeutics shareholders are primarily institutional investors at 96.57%, followed by 1.93% insiders and 1.50% retail investors. The average institutional ownership in Arcutis Biotherapeutics's industry, Biotech Stocks , is 68.48%, which Arcutis Biotherapeutics exceeds.

Who owns the most shares of Arcutis Biotherapeutics?

Arcutis Biotherapeutics’s largest shareholders are Jennison associates (12.34M shares, 9.93%), Suvretta capital management (11.4M shares, 9.17%), and Rubric capital management lp (10.97M shares, 8.82%). Together, they hold 27.92% of Arcutis Biotherapeutics’s total shares outstanding.

Does Blackrock own Arcutis Biotherapeutics?

Yes, BlackRock owns 7.76% of Arcutis Biotherapeutics, totaling 8.62M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 80.19M$. In the last quarter, BlackRock increased its holdings by 1.96M shares, a 29.49% change.

Who is Arcutis Biotherapeutics’s biggest shareholder by percentage of total assets invested?

Pivotal bioventure partners investment advisor is Arcutis Biotherapeutics’s biggest shareholder by percentage of total assets invested, with 19.95% of its assets in 2.12M Arcutis Biotherapeutics shares, valued at 29.54M$.

Who is the top mutual fund holder of Arcutis Biotherapeutics shares?

Polar Capital Biotech S Inc is the top mutual fund holder of Arcutis Biotherapeutics shares, with 5.06% of its total shares outstanding invested in 6M Arcutis Biotherapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools